These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1157 related items for PubMed ID: 33126575

  • 1. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I, Cimini FA, Cavallo MG.
    Nutrients; 2020 Oct 28; 12(11):. PubMed ID: 33126575
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S.
    World J Gastroenterol; 2017 May 21; 23(19):3407-3417. PubMed ID: 28596677
    [Abstract] [Full Text] [Related]

  • 4. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future.
    Barchetta I, Cimini FA, Cavallo MG.
    Nutrients; 2017 Sep 14; 9(9):. PubMed ID: 28906453
    [Abstract] [Full Text] [Related]

  • 5. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
    Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A, Cusi K.
    J Hepatol; 2015 Feb 14; 62(2):405-11. PubMed ID: 25195551
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG.
    BMC Med; 2016 Jun 29; 14():92. PubMed ID: 27353492
    [Abstract] [Full Text] [Related]

  • 8. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model.
    Su YB, Li TH, Huang CC, Tsai HC, Huang SF, Hsieh YC, Yang YY, Huang YH, Hou MC, Lin HC.
    PLoS One; 2018 Jun 29; 13(4):e0194867. PubMed ID: 29684027
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H, Shen Z, Lin Y, Zhang J, Zhang Y, Liu P, Zeng H, Yu M, Chen X, Ning L, Mao X, Cen L, Yu C, Xu C.
    J Biol Chem; 2020 Mar 20; 295(12):3891-3905. PubMed ID: 32051143
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D and nonalcoholic fatty liver disease.
    Zhang Z, Thorne JL, Moore JB.
    Curr Opin Clin Nutr Metab Care; 2019 Nov 20; 22(6):449-458. PubMed ID: 31589177
    [Abstract] [Full Text] [Related]

  • 11. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F.
    World J Gastroenterol; 2014 Jul 14; 20(26):8341-50. PubMed ID: 25024593
    [Abstract] [Full Text] [Related]

  • 12. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S, Sohrabpour AA, Foroughi F, Alvandi E, Esmaillzadeh A.
    Trials; 2019 Mar 04; 20(1):153. PubMed ID: 30832722
    [Abstract] [Full Text] [Related]

  • 13. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease.
    Sangouni AA, Ghavamzadeh S, Jamalzehi A.
    Diabetes Metab Syndr; 2019 Mar 04; 13(3):2260-2265. PubMed ID: 31235166
    [Abstract] [Full Text] [Related]

  • 14. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ, Yu HC, Li Y, Zhang YB, Geng TT, Lu Q, Liao YF, Guo KQ, Du L, Ruan HL, Yang K, Liu G, Pan A.
    Am J Clin Nutr; 2022 Nov 04; 116(5):1409-1417. PubMed ID: 36107812
    [Abstract] [Full Text] [Related]

  • 15. Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action.
    Elhafiz M, Zhao G, Ismail M, Xu D, Das D, Fan S, Cheng N, Yousef BA, Jiang Z, Zhang L.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun 04; 1865(6):158657. PubMed ID: 32045698
    [Abstract] [Full Text] [Related]

  • 16. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A.
    Int J Mol Sci; 2024 May 22; 25(11):. PubMed ID: 38891828
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.